Dermatology and Immunoglobulin Therapy: Who to Treat and How to Administer Immunoglobulins

Actas Dermosifiliogr (Engl Ed). 2018 May;109(4):323-330. doi: 10.1016/j.ad.2017.11.009. Epub 2018 Feb 9.
[Article in English, Spanish]

Abstract

Intravenous immunoglobulin (IVIG) replacement therapy has been used in immune deficiency diseases for more than 50 years. The indications for this treatment have evolved, however, and IVIG therapy is now used in various diseases in which the immune system plays a prominent role. IVIG therapy has carved out a niche in dermatology for the treatment of such conditions as dermatomyositis, autoimmune bullous diseases, and toxic epidermal necrolysis. Special attention has been paid to this therapy in recent years. New guidelines have been published and should be taken into consideration in dermatology. This review provides a practical guide to IVIG use in our specialty.

Keywords: Autoimmune bullous diseases; Dermatology; Dermatología; Dermatomiositis; Dermatomyositis; Enfermedades autoinmunes ampollares; Inmunoglobulinas intravenosas; Intravenous immunoglobulin therapy; Necrólisis epidérmica tóxica; Toxic epidermal necrolysis.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases / therapy
  • Contraindications, Drug
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage
  • Immunoglobulins, Intravenous / adverse effects
  • Immunoglobulins, Intravenous / therapeutic use*
  • Infusions, Subcutaneous
  • Patient Selection
  • Practice Guidelines as Topic
  • Premedication
  • Skin Diseases / therapy*

Substances

  • Immunoglobulins, Intravenous